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1. Introduction 
Atherothrombosis is the main underlying determinant of cardiovascular diseases, which 
remain the leading cause of death in developed countries. Multiple lines of evidence now 
support the concept of atherothrombosis as a chronic inflammatory disease of the arterial 
wall.1, 2 This process involves a complex interplay between modified lipids and cells of the 
immune and vascular system, which usually evolves into the formation of atherosclerotic 
lesions yielding a stable necrotic plaque. If left untreated, plaque rupture and thrombosis 
may ensue, leading to important clinical manifestations, such as acute coronary syndromes 
and sudden death.3 
As the incorporation of modified low-density lipoproteins in the arterial wall represents a 
important step in the onset of atherothrombosis, the subsequent recruitment and activation 
of inflammatory cells, including monocytes, B- and T-lymphocytes, neutrophils and 
platelets play a critical role in the pathogenesis of this disease.4 These cells exhibit pro-
atherogenic functions through multiple co-stimulatory and immune molecules present on 
their cell surface. Among these, the CD40L/CD40 receptor-ligand pair has been the focus of 
much attention, such that this dyad is now regarded as a pivotal contributor to all 
underlying phases of atherothrombosis.5-7 Indeed, the CD40L/CD40 interaction exerts a 
wide array of biological functions at the forefront of the pathophysiology of this disease and 
disruption of this cascade by both pharmacological and genetic approaches have shown 
beneficial results in animal and clinical studies.8-11 While CD40L is known to mainly interact 
with its classical receptor CD40, additional binding partners have been described, namely 
the integrins ǂIIbǃ3, ǂMǃ2 and ǂ5ǃ1. This chapter discusses the role of CD40L and its receptors 
in the pathophysiology of atherothrombosis, while highlighting its therapeutic potentials in 
the treatment of this chronic inflammatory disease.  
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2. The CD40L system 
2.1 CD40L 
CD40L, also known as CD154, is a 39 kDa transmembrane protein belonging to the tumor 
necrosis factor (TNF) superfamily originally identified on cells of the immune system.12, 13 
The interaction of CD40L with its respective receptor on B cells, CD40, a glycoprotein also 
from the TNF receptor (TNFR) family, is of critical importance for immunoglobulin isotype 
switching during the immune response.14 The importance of this interaction is highlighted 
by the pathophysiological manifestations seen in patients suffering from the X-linked hyper-
immunoglobulin-M syndrome, in which B-cells fail to produce the immunoglobulin’s IgG, 
IgA and IgE as a consequence of a genetic mutation in the CD40L gene.15 Because of its wide 
distribution across cells of the vascular system (endothelium, B and T lymphocytes, 
neutrophils, platelets, monocytes, dentritic cells and smooth muscle cells), the CD40L/CD40 
dyad also shares important implications in cell-mediated immunity. CD40L-induced 
signaling in these cells leads to the up-regulation of adhesion and co-stimulatory molecules, 
and the production of pro-inflammatory cytokines, chemokines, growth factors, matrix 
metalloproteinases (MMPs) and procoagulants.16-19 These cellular events are also the main 
mechanisms by which CD40L regulates numerous inflammatory disorders, in particular 
atherothrombosis and its related complications. In fact, circulating levels of soluble CD40L 
(sCD40L), which originate from the proteolytic cleavage of membrane-bound CD40L at the 
surface of activated platelets, have now emerged as strong indicators of cardiovascular 
events such as atherothrombosis and acute coronary syndromes.20-22 
2.2 CD40L receptors  
CD40 
CD40 is the classical high affinity receptor for CD40L. It is constitutively or inducibly 
expressed by most cells of the vascular system (hematopoietic and non-hematopoietic cells) 
and represents the main signaling molecule in the CD40L/CD40 receptor-ligand pair.23 The 
cytoplasmic domain of CD40 bears signaling domains required for the association of 
binding proteins termed TNF receptor-associated factors (TRAFs).24 During humoral 
immunity, a tight interplay between dendritic cells, T-lymphocytes and B-lymphocytes 
occurs, throughout which the activation of CD40 provides a crucial signal for the activation, 
differentiation and secretion of immunoglobulins by B cells.25 Moreover, CD40 activation in 
these cells induces an important anti-apoptotic signal that facilitates cell survival and 
differentiation, primarily through activation of the anti-apoptotic proteins Bcl-XL, A20, Bfl-1 
and Mcl-1, which protect against Fas ligand and TNF-induced cell death.26 As discussed 
above, CD40 signaling plays a significant role in cell-mediated immunity, an important 
aspect by which the CD40L/CD40 dyad initiates and exacerbates atherosclerotic lesions. For 
instance, CD40 activation on endothelial cells induces the up-regulation of a plethora of 
proinflammatory adhesion molecules, cytokines, chemokines, matrix metalloproteinases 
and procoagulants.16 In addition, it has been demonstrated that upon CD40L binding CD40 
activation on platelets can enhance platelet function and promote the secretion of 
inflammatory cytokines involved in plaque formation (this aspect will be discussed in 
greater detail bellow).27-29  
www.intechopen.com
 
CD40 Ligand and Its Receptors in Atherothrombosis 81 
CD40-TRAF dependent signaling 
The engagement of CD40 by CD40L promotes the clustering of CD40 and induces the 
association of TRAFs to the cytoplasmic domain of CD40.30 These adapter proteins are 
essential for the activation of different signaling pathways including the canonical and non-
canonical nuclear factor κB (NF-κB)-signaling pathways and the activation of mitogen-
activated protein kinases (MAPKs).30 The TRAF family comprises six known members, among 
which TRAF-1, -2, -3, -5 and -6 have been shown to drive CD40-dependent cellular responses.  
TRAF-1 can only bind weakly to the cytoplasmic tail of CD40 and therefore regulates the 
signaling of others TRAF members, in particular TRAF-2.30, 31 Indeed, TRAF-1 deficiency in 
antigen presenting cells and B-lymphocytes leads to a significant reduction in the 
recruitment of TRAF-2 to CD40, indicating that TRAF-1 facilitates the association of TRAF-2 
to the cytoplasmic domain of CD40.32, 33 In agreement with these results, it has been shown 
that the recruitment of both TRAF-1 and TRAF-2 are required for complete activation of NF-
κB in B-cells, since the knockout of both genes results in a greater inhibition of the NF-κB 
signaling pathway, in comparison to single knockouts.33 
TRAF-2 is an important contributor to CD40 signaling and its major role resides in the 
activation of the NF-κB signaling pathway, as well as the activation of the p38, Akt and JNK 
MAPKs. CD40 bears a direct binding site for TRAF-2 and blockage of this interaction leads 
to immune deficiencies such as B-cell proliferation and isotype switching.24, 34 Despite its 
significant implications in CD40 signaling, TRAF-2 deficiency may be overcome by TRAF-6 
activation. This was confirmed by data showing that binding of either TRAF-2 or TRAF-6 
alone may activate the NF-κB pathway, while inhibition of both these members completely 
abolishes CD40-dependant B-cell activation, suggesting that both members collaborate for 
the activation of this critical signaling cascade.35-37 
TRAF-3 functions as a negative regulator of CD40 signaling through its constitutive 
association with TRAF-2.38, 39 In absence of stimulation, TRAF-3 interacts with TRAF-2, 
which allows the degradation of the NF-κB inducing kinase (NIK) protein, a critical 
stimulator of NF-κB.40 TRAF-3 deficiency in B cells exacerbates NF-κB and JNK activation, 
primarily through cytosolic accumulation of NIK, thus confirming the negative regulatory 
functions of TRAF-3 in B cells.41  
Very little information is available regarding the role of TRAF-5 in CD40 signaling. 
Nevertheless, it appears that TRAF-5 can interact with TRAF-3 to modulate NF-κB 
activation in B cells. This was shown by experiments in which TRAF-5 deficiency diminishes 
NF-κB activation, causing a reduction in cell activation, expression of co-stimulatory 
molecules and antibody production.42, 43 
TRAF-6 plays a significant role in the activation of key CD40-dependent signaling 
pathways, such as NF-κB, p38, JNK and Akt.44 As discussed above, TRAF-6 synergizes with 
TRAF-2 in order to regulate the activation of NF-κB. Although TRAF-6 contains a direct 
binding site for CD40, specific inhibition of this domain shows lesser inhibitory effects than 
ablation of the complete protein, indicating that TRAF-6 may still have a functional role in 
CD40 signaling without binding directly to CD40.30, 45 Indeed, one of the main functions of 
TRAF-6 resides in its ability to interact with TRAF-2, which is already bound to CD40, and 
facilitate the activation of downstream targets. 
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Recently, a study aiming at evaluating the implication of TRAF members in neointima 
formation, a critical step of atherothrombosis, was conducted. Using a CD40 transgenic mouse 
model, in which mutations at the TRAF2/3/5, TRAF6 or TRAF2/3/5/6 binding sites were 
carried out, the authors conclude that the CD40-TRAF6 axis is a key regulator of inflammatory 
cell infiltration and neointima formation at sites of vascular injury.46  
Although most vascular complications associated to CD40L, including atherothrombosis, 
have been largely attributed to its interaction with CD40, recently identified additional 
receptors merit attention. These include the integrins ǂIIbǃ3, ǂ5ǃ1 and ǂMǃ2 and  (Figure 1). 
 
Fig. 1. CD40L and its receptors. The binding of CD40L to its classical CD40 counterreceptor 
regulates numerous critical biological responses. These mainly include B-cell dependent 
isotype switching, cell-mediated immunity (production of cytokines, chemokines, adhesion 
molecules, growth factors, MMPs and procoagulants) and apoptosis. The CD40L/CD40 
interaction is at the forefront of the pathogenesis of multiple inflammatory disorders, 
including atherothrombosis. The interaction of CD40L with the ǂIIbǃ3 platelet integrin is 
involved in thrombus stabilization and may provide a novel outside-in signaling pathway 
by which platelets can be activated. CD40L can also bind to the inactive conformation ǂ5ǃ1 
and this interaction was shown to induce activation of the human monocytic U937 cell line. 
Finally, ǂMǃ2 can mediate CD40L-dependent inflammatory responses, in particular 
leukocyte adhesion and neointimal formation. The pathophysiological relevance of these 
novel CD40L-mediated interactions in inflammation remains elusive and additional studies 
will be required to address this issue. 
┙IIb┚3 
The ǂIIbǃ3 integrin is the most abundant receptor of the surface of platelets and mediates 
platelet adhesion and aggregation. Like all molecules of the integrin family, it will change 
conformation upon inside-out cellular activation, thereby allowing binding to its natural 
ligands (fibrinogen, fibronectin, vWF...).47 These ligands contain KGD sequences and 
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binding is mediated through the KGD recognition domain present on the ǂIIbǃ3 molecule. 
Interestingly, CD40L also contains a KGD sequence making its interaction with ǂIIbǃ3 
possible. Binding of CD40L to ǂIIbǃ3 was shown to induce phosphorylation of tyrosine 
residues within the cytoplasmic domain of the ǃ3 subunit and appears essential for 
thrombus stabilization in vivo.48, 49 Indeed, CD40L-/- mice exhibit unstable thrombi, which 
can be overcome by infusion of wild type recombinant human CD40L and not CD40L 
specifically mutated at the site of interaction with ǂIIbǃ3.48  
┙5┚1 
The ┙5┚1 integrin was also shown to act as a CD40L receptor.50 Indeed, sCD40L can bind 
and activate cells of the undifferentiated human monocytic U937 cell line in a CD40- and 
ǂIIbǃ3-independent manner. Binding to this cell line was reversed by an anti-┙5┚1 antibody, 
as well as in the presence of soluble ┙5┚1, thus confirming ┙5┚1 specificity. Moreover, this 
interaction is unaffected by pre-treatment of CD40L with soluble CD40, indicating that 
CD40L can bind both CD40 and ┙5┚1 concomitantly.50 Interestingly, CD40L binds to inactive 
┙5┚1, contrary to most ligands of the integrin family. However, the physiological relevance 
of this interaction remains unexplored and additional studies are needed to fully 
characterize the interplay that might take place between CD40L and ┙5┚1 in inflammatory 
disorders.  
┙M┚2 
The ǂMǃ2 (Mac-1) integrin mediates firm adhesion of leukocytes to inflamed vessels by 
interacting with its endothelial cell counterreceptor intercellular adhesion molecule 1 
(ICAM-1).51 CD40L was also recently shown to bind to active ǂMǃ2 and this interaction may 
represent an alternative pathway for CD40L-mediated inflammation.52 Indeed, inhibition of 
this novel CD40L binding partner significantly attenuates leukocyte accumulation at sites of 
inflammation and reduces atherogenesis, indicating that CD40L may promote, at least in 
part, atherosclerotic lesions in a ǂMǃ2-dependent manner. Again, the relative contribution 
of this CD40L receptor (in comparison to CD40) in the development of inflammatory 
disorders such as atherothrombosis remains unknown. Perhaps, each of these CD40L 
receptors may interfere at different stages of the disease, thus contributing to 
proinflammatory reactions and atherogenesis in their own way.   
3. CD40L in atherothrombosis  
The involvement of CD40L in the pathogenesis of atherothrombosis is supported by 
numerous studies. Targeting of CD40L by both pharmacological and genetic approaches has 
highlighted the importance of this molecule in all stages of the disease. In 1998, Mach et al. 
showed that treatment of hyperlipidemic LDLR-/- mice with an anti-CD40L antibody 
significantly ameliorates the size and lipid contents of atherosclerotic lesions.53 These results 
were further confirmed by a genetic approach, which showed that CD40L-/-/ApoE-/- mice 
exhibit considerably smaller plaque area than control ApoE-/- mice.8 Moreover, these 
animals display enhanced collagen fibrils within the fibrous cap of lesions, a key component 
of plaque stability. In an additional study, the administration of an anti-CD40L antibody in 
ApoE-/- mice, at the onset of lesions or once atherosclerotic lesions are fully established, 
reduces lipid contents and increases plaque stability.54 Taken together, these studies support 
the contribution of CD40L in plaque initiation, progression and stability (Figure 2). 
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Fig. 2. Role of CD40L in atherothrombosis. The incorporation of oxidized LDLs, among 
other factors, may upregulate the expression of the CD40L system on the endothelium, 
thereby promoting the recruitment of platelets and leukocytes at the sites of injury. The 
CD40L-dependent adhesion of T-lymphocytes and platelets to the endothelium induces an 
important inflammatory response characterized by the secretion of various cytokines and 
the upregulation of additional endothelial adhesion molecules. This favors in turn the 
incorporation and transmigration of additional leukocytes, in particular monocytes. Once in 
the sub-endothelial space, CD40L/CD40 interactions between foam cells (macrophages 
which have undergone phagocytosis of oxidized LDL particules), T-lymphocytes and 
smooth muscle cells take place. These cross talks ultimately lead in part to the proliferation 
of smooth muscle cells into the intima and promote vascular angiogenesis, primarily 
through the secretion of key inflammatory and angiogenic cytokines and chemokines. This 
process eventually yields a stable lipid-enriched atherosclerotic plaque surrounded by a 
fibrous cap. Plaque stability is threatened by the production of MMPs, which are directly 
responsible for collagen degradation and rupture of the fibrous cap. The binding of CD40 on 
endothelial cells, macrophages and smooth muscle cells can provoke the secretion of a long 
list of MMPs. Following rupture, platelets rapidly adhere to the surface of the highly pro-
thrombotic contents of the atherosclerotic plaque, thereby leading to thrombus formation 
and arterial occlusion. CD40L may also be involved in thrombus formation and 
procoagulant activity. CD40L binding to the endothelium promotes tissue factor expression, 
while the binding of CD40L (soluble and membrane-bound forms) to CD40 and ǂIIbǃ3 on 
platelets enhances platelets aggregation and thrombus stabilization, respectively.  
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3.1 Initiation of lesions and leukocyte recruitment 
Plaque initiation is normally characterized by the accumulation of low-density lipoproteins 
(LDL) in the arterial wall and the subsequent recruitment and transmigration of leukocytes 
within the sub-endothelial space.1 The initial trigger of CD40L (and CD40) expression within 
cells of the developing atherosclerotic plaque (endothelial cells, lymphocytes, platelets, 
monocytes/macrophages, and smooth muscle cells) remains elusive. Possible candidates 
include oxidized LDL, infectious pathogens and alterations in vascular hemodynamic forces.55-
57 For instance it has been demonstrated that lipid lowering reduces CD40L expression in 
atheroma.55 In addition, oxidized LDL were reported to induce the expression of CD40 on 
endothelial cells, which can then bind CD40L from activated T-lymphocytes adherent to the 
site of injury.58 CD40 activation on endothelial cells provides a critical proinflammatory signal 
for the initiation of lesions. Indeed, the CD40L/CD40 interaction favors the up-regulation of 
adhesion molecules (E-selectin, P-selectin, vascular cell adhesion molecule-1 [VCAM-1] and 
ICAM-1) and leads to the secretion of proinflammatory cytokines (IL-6, IL-8, IL-15, monocytes 
chemotactic protein-1 [MCP-1], macrophage inflammatory protein-1 [MIP-1 ǂ/ǃ] and 
regulated on activation normal T cell expressed and secreted  [RANTES]) by the 
endothelium.6, 7, 59-62 These reactions induce in turn the incorporation and accumulation of 
additional leukocytes, in particular monocytes, at the sites of developing lesions.  
As discussed above, ǂMǃ2, an integrin expressed on neutrophils and monocytes/ 
macrophages, has been identified as a receptor for CD40L. This interaction may also mediate 
adhesion and migration of inflammatory cells at sites of plaque initiation. In agreement with 
this hypothesis, ǂMǃ2 deficiency attenuates lesion development and reduces lesional 
macrophage accumulation in LDLR-/- mice, supporting the implication of this integrin in 
atherothrombosis.52 However, additional studies will be required to specifically establish the 
importance of the CD40L/ǂMǃ2 in plaque initiation.       
In addition, platelets have been shown to play a crucial role in the initiation of 
atherothrombosis. Platelets are among the first inflammatory cells at the site of injury and 
their adhesion to the endothelium provides a fundamental mechanism by which leukocytes 
are recruited.63, 64 Because the surface of activated platelets contains a higher density of P-
selectin than activated endothelial cells, significantly more leukocytes will incorporate at the 
sites of injury in their presence.65 Interestingly, CD40L from activated platelets can also 
induce a proinflammatory response on endothelial cells, in a similar fashion to that of T-
lymphocytes. Henn et al. demonstrated that CD40 ligation on endothelial cells by CD40L 
from activated platelets induces the expression of numerous adhesion molecules, cytokines, 
and matrix metalloproteinases involved in the initiation of inflammatory reactions.16     
3.2 Plaque development and progression 
The progression of the atherosclerotic plaque is typically highlighted by the proliferation 
and migration of smooth muscle cells into the intima, as well as the formation neovessels 
(angiogenesis), which supports the growth of lesions. This process will eventually yield a 
stable lipid-enriched necrotic plaque surrounded by a fibrous cap. Once in the sub-
endothelial space, macrophages (originally monocytes) undergo phagocytosis of oxidized 
LDL particles, leading to the formation of foam cells.66 Thereafter, CD40L from infiltrated T-
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lymphocytes will bind to CD40 on the surface of differentiated foam cells, favoring the 
release of further proinflammatory cytokines (IL-1, IL-6 and IL-12), growth factors (vascular 
endothelial growth factor [VEGF]) and MMPs (MMP-1 and MMP-3).7, 67 These responses are 
intimately involved in the proliferation and migration of smooth muscle cells into the intima 
layer. In parallel, cross talks between smooth muscle cells and T-lymphocytes may also take 
place, in which CD40 activation on the former initiates a positive feedback loop enhancing 
the inflammatory reactions already in place.6 Indeed, CD40 signaling in smooth muscle cells 
has been shown to induce the secretion of the cytokines IL-8 and MCP-1.67, 68 Moreover, the 
accumulation of migrating fibroblasts within the intima layer exacerbates the atherosclerotic 
lesions in development and the CD40L/CD40 axis might also takes part in this process.69 
Stimulation of fibroblasts with CD40L was reported to up-regulate the expression of cell 
surface adhesion molecules, thus facilitating their interaction with immune cells at the site of 
lesions.70 This interaction also induces their proliferation and secretion of chemoattractant 
cytokines such as IL-6 and IL-8.71-73 Hence, the CD40L/CD40 interaction is at the forefront of 
a plethora of key inflammatory reactions involved in neointima formation and plaque 
accumulation. Lesions with eventually develop into the formation of a stable necrotic core 
consisting of infiltrated leukocytes, foam cells, proliferating smooth muscle cells, extra-
cellular matrix proteins and lipids. 
The formation of neovessels or angiogenesis plays an integral part in plaque progression 
and several reports have highlighted the importance of CD40L in this process. For instance, 
CD40 ligation on endothelial cells and macrophages was shown to upregulate the 
expression of potent angiogenic factors such as VEGF, fibroblast growth factor and platelet-
activating factor, in addition to inducing the synthesis and proteinase activity of various 
MMPs such as MMP-1, MMP-2, MMP-3 and MMP-9.18, 74-76 These responses are tightly 
linked to tubule formation and angiogenesis, essential elements of plaque support and 
growth. Interestingly, the ǂ5ǃ1 integrin is upregulated on angiogenesis-prone endothelial 
cells and could also provide a novel mechanism by which CD40L modulates pathological 
angiogenesis.77 It would be worthwhile investigating this issue in further details.  
3.3 Plaque instability and thrombosis 
Plaque stability is regulated by a tight balance between extracellular matrix proteins such as 
collagen fibers and MMP production. A thin fibrous cap protects the highly thrombotic 
components of the atherosclerotic plaque. However, upon secretion of MMPs by 
macrophages and other inflammatory cells present, plaque rupture may ensue following 
digestion of the collagen fibers within the fibrous cap.78, 79 This process leads to thrombus 
formation and may cause complete obstruction of the artery. CD40L mediates several of the 
processes that set the stage for plaque rupture and its clinical sequelae. CD40L stimulation 
on endothelial cells, macrophages and smooth muscle cells can provoke the secretion of a 
long list of MMPs (MMP-1, MMP-2, MMP-3, MMP-8, MMP-9 and MMP-13), the main 
digestive enzymes of the collagen-rich fibrous cap.18, 80, 81 Platelets, in addition to their 
pivotal role in thrombosis, also participate in this process. Indeed, membrane-bound CD154 
expressed on the surface of activated platelets can induce MMP upregulation in endothelial 
cells.82 MMP secretion and proteolytic activity can be abrogated by physical hindrance of 
platelet-endothelial contacts, ǂIIbǃ3 interfering agents or anti-CD40L antibodies, thus 
highlighting in part the importance of platelets and CD40L in this phenomenon.  
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Following rupture, platelets rapidly adhere to the surface of the highly pro-thrombotic 
contents of the atherosclerotic plaque, thereby leading to thrombus formation and arterial 
occlusion.83, 84 Accumulating evidence also support a role for CD40L in platelet function and 
thrombus formation, albeit some of the data remain conflicting. For instance, Andre et al. 
have shown that CD40L plays a role in thrombus stabilization by interacting with ǂIIbǃ3, 
while we and others have demonstrated that CD40L enhances platelet aggregation and 
thrombus formation through a CD40-mediated TRAF-2/Rac1/p38 signaling pathway.27, 28, 48 
Indeed, enhanced levels of circulating sCD40L exacerbate thrombus formation in vivo, also 
in a CD40-dependent fashion.27 Nevertheless, these studies all support the concept of CD40L 
as a pro-thrombotic agent, predisposing platelets to enhanced cell function. CD40L may also 
enhance the coagulation system through the induction of tissue factor release from various 
vascular cells. CD40 engagement on endothelial cells, macrophages and smooth muscle cells 
by CD40L from activated platelets or T cells induces tissue factor expression and activity.85-87 
Besides its important role in the induction of the extrinsic coagulation cascade, tissue factor 
also represents a powerful platelet agonist.  
4. Soluble CD40L and coronary syndromes 
Given the pivotal contribution of the CD40L system in atherothrombosis, multiple clinical 
studies have evaluated the association between levels of circulating sCD40L and 
cardiovascular risk, in particular acute coronary syndrome (ACS) such as acute myocardial 
infarction (AMI) and unstable angina (UA). These studies can be divided into two main 
categories. The first type of clinical studies has investigated the link between levels of 
sCD40L and ACS, while the second has determined the link between levels of sCD40L and 
prognosis and risk prediction. 
For the most part, clinical studies demonstrate that circulating sCD40L levels are 
significantly higher in patients with ACS and stable coronary artery disease (CAD), 
compared with control subjects.88-92 Indeed, it appears that a gradual increase in sCD40L 
levels occurs with ACS progression, with peaks as early as 9 hours following the onset of 
AMI or UA.89, 93, 94 For instance, patients suffering from AMI or UA present with levels 
ranging from 5-25 ng/mL, depending on the study.88 Moreover, sCD40L levels are 
independent from other important inflammatory markers, such as IL-6, sICAM-1, sVCAM-
1, C-reactive protein and troponin, indicating that sCD40L may represent a more reliable 
risk factor, as compared to others.92 Because sCD40L in circulation almost exclusively 
originates from the shedding of membrane-bound CD40L at the surface of activated 
platelets, its measuring levels may reflect a state of platelet activation rather than an 
inflammatory condition.  
More importantly, some clinical studies have evaluated the relationship between sCD40L 
levels and disease prognosis. In the CAPTURE (c7E3 Fab Anti-Platelet Therapy in unstable 
Refractory Angina) trial, patients with high levels of sCD40L were 3-fold more at risk of 
developing cardiovascular death or AMI.21 Moreover, in the MIRACL (Myocardial Ischemia 
Reduction with Aggressive Cholesterol Lowering) study, sCD40L levels were an 
independent risk factor for recurrent cardiovascular events, such as death, nonfatal 
myocardial infarction, cardiac arrest and worsening angina requiring rehospitalization.95 
Interestingly, individuals carrying the -3459A>G polymorphism on the CD40L gene, are 
more at risk of developing AMI.96 
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Whether enhanced levels of sCD40L seen in patients with ACS are a consequence of 
increased platelet activation or a predetermining cause of these complications (or perhaps 
both) is still unknown. Recently, we have shown that enhancing levels of circulating sCD40L 
in mice to approximately 45 ng/mL exacerbates thrombus formation in a CD40-dependent 
manner.27 This observation supports the idea that increased levels of sCD40L in patients 
may drive, at least in part, the development of certain cardiovascular complications. It 
would be tempting to speculate the existence of a positive feedback loop taking place in 
these patients, where disease initiation correlates with platelet activation and release of 
sCD40L in the circulation. This in turn could further exacerbate pre-existing complications 
through enhancement of platelet function and thrombus formation.  
5. Disruption of the CD40L system as a therapeutic target in 
atherothrombosis 
In light of all the aforementioned data supporting the contribution of CD40L in 
inflammation, disruption of this system as a therapeutic strategy for the treatment of 
atherothrombosis and its clinical manifestations has been investigated. Unfortunately, 
clinical trials using an anti-CD40L antibody were put on hold due to thromboembolic 
complications.97, 98 Interactions between CD40 and CD40L-immune complexes at the surface 
of platelets have been suggested as a possible mechanism by which CD40L therapy induces 
these complications.97  
Since circulating levels of sCD40L result from platelet activation, indirect targeting of the 
CD40L system through anti-platelet therapy may represent an alternative approach to 
suppress this important component. Clopidogrel, a potent inhibitor of the platelet adenosine 
diphosphate (ADP) receptor, has been reported to block sCD40L release from ADP-
stimulated platelets.99 Interestingly, clopidogrel regiment significantly reduces platelet 
CD40L expression and sCD40L levels in patients with stable CAD.100 Moreover, ǂIIbǃ3 
inhibitors, such as abciximab, inhibit platelet aggregation and sCD40L release from 
activated platelets.101 In the CAPTURE trial, abciximab significantly reduces sCD40L levels 
and cardiovascular risk in high-risk ACS patients, confirming a link between ǂIIbǃ3 
signaling and platelet sCD40L release.21  
Statins exert multiple pleiotropic anti-inflammatory effects, in addition to their lipid 
lowering properties. Several reports have investigated the effects of these drugs on 
inflammatory markers, including CD40L. Particularly, they have been shown to reduce 
cytokine-induced CD40L expression on endothelial cells, smooth muscle cells and 
macrophages.102 Notably, atorvastatin treatment in the MIRACL trial reduces the risk of 
recurrent cardiovascular events, which are associated with sCD40L levels.95  
Most of these agents indirectly target the CD40L system, perhaps through inhibition of 
platelet activation and the subsequent release of sCD40L. Specific disruption of CD40L or its 
receptors remains a promising approach for the treatment of atherothrombosis. Although 
clinical studies using anti-CD40L antibodies have been unsuccessful, alternative targets of 
this system may render better clinical outcomes. For example, novel anti-CD40L agents that 
specifically target the interaction of CD40L with its different receptors or inhibition of 
critical intracellular signaling elements, such as TRAFs, represent valuable approaches. 
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6. Conclusions 
Research over the years overwhelmingly supports the notion of atherothrombosis as a 
chronic inflammatory disease. Despite the plethora of inflammatory mediators identified 
thus far as potential contributors to this complication, the CD40L system has attracted a 
great deal of interest. Besides its pivotal role in humoral immunity, CD40L is now regarded 
as a key player to all major phases of atherothrombosis, a concept supported in part by the 
strong relationship between its circulating soluble levels and the occurrence of 
cardiovascular diseases. In addition to its well-established CD40 counterreceptor, CD40L 
can also interact with novel binding partners, namely the integrin receptors ǂIIbǃ3, ǂMǃ2 and 
ǂ5ǃ1. Although most CD40L-mediated functions have been attributed to its interaction with 
CD40, these novel receptors add complexity to the diverse interplays that might take place 
during inflammation. The elucidation of the exact physiopathological relevance of these 
interactions in inflammatory disorders might pave the way for the development of novel 
anti-CD40L therapeutic targets for the treatment of atherothrombosis and cardiovascular 
diseases.  
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analyzes several aspects of clinical pharmacology.
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